CER Daily Newsfeed

What Will Make Real-World Evidence Regulatory Grade in 2026 and Beyond?

(3/11, Premier Blog) comments “...‘RWD now informs nearly every type of evidence generation we do, including truly randomized control trials,’ said [Jennifer Webster, Pfizer’s Vice President, RWE Platforms and Partnerships]. ‘We still use RWD to inform site selection. We are also conducting more pragmatic or low-interventional trials, where most of the data is coming from real-world settings, but we may collect a few additional labs or instrument measures. On the observational side, we often combine retrospective data with primary data collection, sometimes within the same study. This helps ensure each protocol is carefully calibrated to deliver the specific evidence we’re targeting.’” Full

V-BID Summit 2026 Highlights Value-Based Care and Equity With CMMI Director

(3/11, Sabrina McCrear, The American Journal of Managed Care) reports “...Because AI can be used exponentially, unregulated use could make health care more expensive, especially when based on patient outcomes rather than overall patient health. Instead, [CMMI director Abe Sutton] suggested shifting toward paying for health outcomes rather than specific technical activities, rather than focusing on the technology itself. This approach enables a ‘productivity unlock’ in which technology, such as AI, can be applied in a deflationary manner.” Full

Norwegian Industry Asks Government To Match Danish Response To US Pricing Pressures

(3/11, Francesca Bruce, Pink Sheet) reports “...Norway’s pharmaceutical industry association says it is waiting to hear from the ministry of health about how it will address the country’s low willingness to pay for innovation.” Subscription Required